NYSE:WAT - Waters Stock Price, Price Target & More

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Waters announced that its board has initiated a stock buyback program on Tuesday, April 24th 2018, which permits the company to buyback $3,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 18.2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's management believes its stock is undervalued.

Waters Co. (NYSE:WAT) released its quarterly earnings results on Tuesday, April, 24th. The medical instruments supplier reported $1.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.55 by $0.04. The medical instruments supplier earned $530.70 million during the quarter, compared to analyst estimates of $534.17 million. Waters had a net margin of 1.14% and a return on equity of 25.80%. The firm's revenue for the quarter was up 6.6% on a year-over-year basis. During the same period last year, the business earned $1.46 earnings per share. View Waters' Earnings History.

Waters is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Waters.

Waters issued an update on its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share (EPS) guidance of $8.10-8.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.19.

16 brokers have issued 1 year price targets for Waters' shares. Their forecasts range from $180.00 to $230.00. On average, they anticipate Waters' share price to reach $204.7857 in the next year. This suggests a possible upside of 4.7% from the stock's current price. View Analyst Ratings for Waters.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Waters in the last year. There are currently 2 sell ratings, 10 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Waters include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), Bio-Rad Laboratories, Inc. Class B (BIO.B), PerkinElmer (PKI), Integra Lifesciences (IART), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM) and Harvard Bioscience (HBIO).

Press coverage about WAT stock has trended somewhat positive recently, Accern reports. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Waters earned a coverage optimism score of 0.11 on Accern's scale. They also gave news coverage about the medical instruments supplier an impact score of 45.76 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Waters' stock is owned by many different of retail and institutional investors. Top institutional investors include Fenimore Asset Management Inc. (0.37%), Bank of Montreal Can (0.11%), Copper Rock Capital Partners LLC (0.08%), Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%), State of Alaska Department of Revenue (0.02%) and Denali Advisors LLC (0.02%). Company insiders that own Waters stock include Arthur G Caputo, Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Ian King, Joann A Reed, Laurie H MD Glimcher, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Institutional Ownership Trends for Waters.

WAT stock was sold by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., State of Alaska Department of Revenue, Fenimore Asset Management Inc., Copper Rock Capital Partners LLC, Gateway Investment Advisers LLC and Raymond James Trust N.A.. Company insiders that have sold Waters company stock in the last year include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Joann A Reed, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Insider Buying and Selling for Waters.

WAT stock was bought by a variety of institutional investors in the last quarter, including DnB Asset Management AS, Bank of Montreal Can, Denali Advisors LLC, Fjarde AP Fonden Fourth Swedish National Pension Fund, IFM Investors Pty Ltd, Pennsylvania Trust Co and Ledyard National Bank. View Insider Buying and Selling for Waters.

Shares of WAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WAT stock can currently be purchased for approximately $195.57.

Waters has a market capitalization of $15.52 billion and generates $2.31 billion in revenue each year. The medical instruments supplier earns $20.31 million in net income (profit) each year or $7.49 on an earnings per share basis. Waters employs 7,000 workers across the globe.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier can be reached via phone at 508-478-2000 or via email at [email protected]